ALINA KIEVSKY: Open Payments
NPI 1295009306 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$952 in 46 payments from 14 companies in 2025. Trend: 2023 $844 · 2024 $864 · 2025 $952
Food & beverage: $952
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $235 |
| Lilly USA, LLC | 7 | $188 |
| Novo Nordisk Inc | 5 | $113 |
| Novartis Pharmaceuticals Corporation | 5 | $95 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $82 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $59 |
| Dexcom, Inc. | 1 | $31 |
| ABBVIE INC. | 1 | $31 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
| Astellas Pharma US Inc | 1 | $20 |
Products named: MOUNJARO, OTEZLA, LEQVIO, XIFAXAN, Wegovy, EVENITY, Repatha, Dexcom G6 Transmitter.
Industry payments across CA — which companies pay providers there.
